Rescue Therapy for Helicobacter Pylori Infection

Summary

Dual therapy containing vonoprazan and amoxicillin had showed excellent eradication results with Helicobacter pylori first-line treatment. However, no study has examined its efficacy for H. pylori rescue treatment. Rifabutin has low antibiotic resistance, superior antibacterial activity in vitro, and stability in the gastric acid environment. Several studies have confirmed the efficacy of rifabutin-containing triple therapy as a first-line or rescue treatment for H. pylori. The purpose of this study was to evaluate the efficacy and safety of dual therapy vesus rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory Helicobacter pylori.

Timeline

Start

2023-05-16

Primary completion

2025-01-31

Completion

2025-01-31

Publications

• Huang Y, Chen JN, Qiu SH, Guo YX, Li MX, Gao YN, Liang X, Han YH, Xu P, Wang J, Lu H. Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial. Lancet Reg Health West Pac. 2026 Feb 12;68:101815. doi: 10.1016/j.lanwpc.2026.101815. eCollection 2026 Mar.

Drugs

Indications